Inhibition of Spontaneous Platelet Aggregation by Sulfinpyrazone

Summary

In a randomized double-blind crossover study in 16 patients with enhanced in vitro spontaneous platelet aggregation, sulfinpyrazone proved to be effective in normalizing platelet aggregability within 4 days after initiation of therapy.

• References

• 1 Ali M, McDonald JW D. 1975; Effects of sulfinpyrazone on platelet prostaglandin synthesis and platelet release of serotonin. Journal of Laboratory and Clinical Medicine 89: 868
• 2 The Anturane Reinfarction Trial Research Group. 1978; Sulfinpyrazone in the prevention of cardiac death after myocardial infarction. New England Journal of Medicine 298: 289
• 3 Ballatori E, Nenci GG. 1975. Piano degli esperimenti per il controllo dell'efficacia di farmaci antiaggreganti piastrinici nella prevenzione della recidiva della trombosi arteriosa. In Proceedings of the 28th Scientific Session, Italian Society of Statistics; Padova: 1975. p 17-31
• 4 Blakely JA, Gent M. 1975. Platelets, drugs and longevity in a geriatric population. In Hirsh J, Cade JF, Gallus AS. et al. (eds.) Platelets, Drugs and Thrombosis. S. Karger; Basel: pp 284-291
• 5 Breddin K, Hoff F. 1968. Die Thrombozytenfunktion bei hämorrhagischen Diathesen. Thrombosen und Gefäßkrankheiten. F. K. Schattauer-Verlag; Stuttgart - New York:
• 6 Breddin K, Krzywanek HJ, Bald M, Kutschera J. 1974. Is enhanced platelet aggregation a risk factor for thromboembolic complications in atherosclerosis. In Caprino L, Rossi EC. (eds.) Platelet Aggregation and Drugs. Academic Press; London: pp 197-212
• 7 Breddin K, Krzywanek HJ, Ziemen J, Bauer H, Grün H. 1977. Enhanced platelet aggregation as a risk factor for progress and complications of vascular disease. New findings with a platelet aggregation test (PAT III) and on the dependence of different aggregation tests on morphologic platelet changes In Agnoli A, Fazio C. (eds.) Platelet Aggregation in the Pathogenesis of Cerebrovascular Disorders. Springer-Verlag; Heidelberg and New York: pp 44-62
• 8 Buchanan M, Hirsh J. 1975; Comparison of in vivo and in vitro effects of platelet function suppressing drugs. Thrombosis et Diathesis Haemorrhagica 34: 552
• 9 Cortellaro M, Fassio G, Deambrogi L, Polli EE. 10.05.1977. Sulfinpyrazone in coronary heart disease. The Anturan Reinfarction Italian Study (ARIS). In Abstracts of the First Florence Conference on Haemostasis and Thrombosis. Florence: p 180
• 10 De Gaetano G. 1975; Pharmacological properties of drugs inhibiting platelet aggregation. Acta Clin. Belg 30: 184
• 11 Essien EM, Mustard JF. 1977; Inhibition of platelet adhesion to rabbit aorta by sulfinpyrazone and acetylsalicylic acid. Atherosclerosis 27: 89
• 12 Evans G. 1972; Effect of drugs that suppress platelet surface interaction on incidence of amaurosis fugax and transient cerebral ischemia. Surgery Forum 23: 239
• 13 Fleming JS, Buyniski JR. 1977; Enhanced platelet aggregability in dogs following myocardial infarction. Life Sciences 20: 843
• 14 Gent M. 1975. Canadian cooperative study of recent recurrent presumed cerebral emboli (RRPCE): Design and organization of the study. In Hirsh J, Cade JF, Gallus AS. et al. (eds.) Platelets, Drugs and Thrombosis. S. Karger; Basel: pp 253-257
• 15 Mustard JF, Packham MA. 1975; Platelets, thrombosis and drugs. Drugs 9: 19
• 16 Packham MA, Mustard JF. 1977; Clinical pharmacology of platelets. Blood 50: 555
• 17 Rosenberg JC, Sell T. 1975; Platelet release and aggregation induced by antithymocyte globulin: in vitro effects of inhibitors. Transplantation 20: 346
• 18 Siegel S. 1956. Non Parametric Statistics. McGraw Hill-Kögakusha; Tokyo:
• 19 Steele P, Battock D, Genton E. 1975; Effect of clofibrate and sulfinpyrazone on platelet survival time in coronary artery disease. Circulation 52: 473
• 20 Steele P, Carroll J, Overfield D, Genton E. 1977; Effect of sulfinpyrazone on platelet survival time in patients with transient cerebral ischemic attacks. Stroke 8: 396